<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267603</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-00848</org_study_id>
    <secondary_id>NCI-2014-00848</secondary_id>
    <secondary_id>CITN-09</secondary_id>
    <secondary_id>MK-3475</secondary_id>
    <secondary_id>CITN-09</secondary_id>
    <secondary_id>CITN-09</secondary_id>
    <secondary_id>K24CA139052</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>U01CA154967</secondary_id>
    <nct_id>NCT02267603</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer</brief_title>
  <official_title>A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well pembrolizumab works in treating patients with Merkel
      cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to
      other parts of the body. Pembrolizumab may stimulate the immune system to identify and
      destroy cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the clinical efficacy of MK-3475 (pembrolizumab) as the first systemic
      intervention for patients with advanced Merkel cell carcinoma (MCC).

      SECONDARY OBJECTIVES:

      I. To determine the clinical activity of MK-3475 as the first systemic intervention for
      patients with advanced MCC.

      TERTIARY OBJECTIVES:

      I. To determine the immune correlates of the clinical activity of MK-3475.

      OUTLINE:

      Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats
      every 21 days for up to 24 months in the absence of disease progression* or unacceptable
      toxicity.

      * NOTE: Patients with confirmed disease progression may continue to receive treatment if they
      are otherwise clinically stable until there is an increase in tumor burden of 25% or more
      following initial confirmation of progression. Under exceptional circumstances, and with
      protocol principal investigator (P.I.) and Cancer Immunotherapy Trials Network (CITN) P.I.
      approval, patients may receive treatment beyond 2 years.

      After completion of study treatment, patients are followed up at 30 days and then every 3
      months for 1 year, every 6 months for 2 years, annually until the patient has completed 3
      years of follow up for disease assessment, and then every 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 25, 2014</start_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) defined as the proportion of patients who have achieved complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>ORR will be estimated as the number of responders as a percent of the number of eligible participants who received at least one dose of treatment. If a substantial amount of data is missing, analyses will be performed using parametric generalized linear models fit by maximum likelihood. A generalized linear model for the ORR will use a binomial error distribution. The model will include as covariates all available baseline predictors of the missing outcomes. Responses to continued pembrolizumab will be chronicled and reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) using RECIST 1.1</measure>
    <time_frame>Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 16 months</time_frame>
    <description>Survival curves for PFS will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Time interval between the date of first response (CR/PR) and the date of progression, assessed up to 3 years</time_frame>
    <description>Survival curves for DOR will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Time interval between the start of treatment to death due to any cause, assessed up to 3 years</time_frame>
    <description>Survival curves for OS will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>Up to 90 days post-treatment</time_frame>
    <description>Safety will be assessed by quantifying the toxicities and grades experienced by subjects including serious AEs (SAEs) and events of clinical interest. Safety and tolerability will be assessed by clinical review of all relevant parameters including AEs, laboratory tests, vital signs, and electrocardiogram measurements. Adverse experiences will be summarized as counts and frequencies by toxicity grade. Summary statistics (median and range) for time to onset of first drug-related toxicity will be provided.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune correlates of the clinical activity of pembrolizumab</measure>
    <time_frame>Baseline</time_frame>
    <description>This will include immunohistochemical and gene expression analysis focusing on delineating the immune components and immunologic milieu within the tumor before therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Merkel polyomavirus (MCPyV)-specific immune response, assessed with enzyme-linked immunosorbent spot and serology assays</measure>
    <time_frame>After 2 years of treatment</time_frame>
    <description>Responses will be assessed at baseline, after initiating therapy, and correlated with clinical responses over time. Among patients with corresponding MHC-peptide tetramers, pre- and post-treatment samples of circulating MCPyV-specific CD8 T cells will be isolated and subjected to deep immunophenotyping by messenger ribonucleic acid (mRNA) expression analysis.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Recurrent Merkel Cell Carcinoma</condition>
  <condition>Stage III Merkel Cell Carcinoma AJCC v7</condition>
  <condition>Stage IIIA Merkel Cell Carcinoma AJCC v7</condition>
  <condition>Stage IIIB Merkel Cell Carcinoma AJCC v7</condition>
  <condition>Stage IV Merkel Cell Carcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression* or unacceptable toxicity.
* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (pembrolizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have biopsy-proven metastatic MCC or locoregional MCC that has recurred
             following standard locoregional therapy with surgery and/or radiation therapy

          -  Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1 assessed by computed tomography (CT) scan, or for skin lesions not
             measurable by CT scan, measurements may be performed with caliper or flexible ruler

               -  Note: stage IV no evidence of disease (NED) is excluded by this criterion

          -  Have a performance status of =&lt; 1 on the Eastern Cooperative Oncology Group (ECOG)
             performance scale

          -  Life expectancy of greater than 6 months

          -  Leukocytes &gt;= 2,000/mcL (labs should be performed within 14 days of treatment
             initiation)

          -  Absolute neutrophil count &gt;= 1,500/mcL (labs should be performed within 14 days of
             treatment initiation)

          -  Platelets &gt;= 100,000/mcL (labs should be performed within 14 days of treatment
             initiation)

          -  Hemoglobin &gt;= 9 g/dL OR &gt;= 5.6 mmol/L (labs should be performed within 14 days of
             treatment initiation)

          -  Serum total bilirubin =&lt; 1.5 x upper limit of normal (ULN) OR direct bilirubin =&lt; ULN
             for patients with total bilirubin levels &gt; 1.5 x ULN (labs should be performed within
             14 days of treatment initiation)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x
             institutional ULN OR =&lt; 5 x ULN for patients with liver metastases (labs should be
             performed within 14 days of treatment initiation)

          -  Serum creatinine =&lt; 2.5 x ULN OR measured or calculated* creatinine clearance (CrCl)
             (glomerular filtration rate [GFR] can also be used in place of creatinine or
             creatinine clearance [CrCl]) &gt;= 30 mL/min for subject with creatinine levels &gt; 2.5 x
             institutional ULN

               -  Creatinine clearance should be calculated per institutional standard (labs should
                  be performed within 14 days of treatment initiation)

          -  Thyroid stimulating hormone (TSH) within institutional limits (i.e.: normal); if TSH
             is greater or less than institutional limits patients may participate if their T4 is
             within normal limits (WNL); patients may be on a stable dose of replacement thyroid
             medication; dose adjustments are allowed if needed (labs should be performed within 14
             days of treatment initiation)

          -  Patients must provide tissue from an archival tumor sample or newly obtained core,
             punch or excisional biopsy of a tumor lesion if deemed relatively safe and technically
             feasible

               -  Note: newly obtained biopsy is preferable

          -  Female patients of childbearing potential must have a negative urine or serum
             pregnancy within 72 hours before receiving the first dose of study medication; if the
             urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
             be required

               -  Note: women of child-bearing potential must agree to use 2 methods of birth
                  control, or be surgically sterile, or abstain from heterosexual activity
                  beginning with the screening visit and for the duration of study participation,
                  through 120 days beyond last dose of MK-3475 administration; patients of
                  childbearing potential are those who have not been surgically sterilized or have
                  not been free from menses for &gt; 1 year; should a woman become pregnant or suspect
                  she is pregnant while she or her partner is participating in this study, she
                  should inform her treating physician immediately

          -  Men treated or enrolled on this protocol must agree to use 2 adequate methods of
             contraception starting with the screening visit, for the duration of study
             participation, and through 120 days after the last dose of MK-3475 administration

          -  Ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patient has had prior systemic therapy for MCC

               -  Note: prior systemic cytotoxic chemotherapy will be allowed if it was
                  administered in the adjuvant setting (no clinically detectable MCC at the time)
                  and treatment concluded more than 6 months prior to beginning study treatment

          -  Patient is currently participating in or has participated in a study of an
             investigational systemic agent to treat MCC; or is using an investigational device
             within 4 weeks of the first dose of treatment

               -  NOTE: if patient received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy

               -  Toxicity from surgery or associated interventions that has not recovered to =&lt;
                  grade 1 is allowed if it meets the inclusion requirements for laboratory
                  parameters

          -  Patients with locoregional disease that have not received appropriate standard
             locoregional therapy with surgery and/or radiation therapy

          -  Patient has had radiation therapy within 2 weeks of beginning study treatment

          -  Toxicity from prior radiation therapy has NOT resolved to grade 1 or less

          -  Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy
             or any other form of immunosuppressive therapy within 7 days prior the first dose of
             trial treatment

          -  Patient has had a prior monoclonal antibody for treatment of MCC

          -  Patient has had a prior monoclonal antibody for a non-cancer therapy indication within
             4 weeks prior to study day 1 or who has not recovered (i.e., =&lt; grade 1 or at
             baseline) from adverse events (AEs) due to agents administered more than 4 weeks
             earlier

          -  Patient has a known additional malignancy that is progressing or requires active
             treatment; exceptions include basal cell carcinoma of the skin, squamous cell
             carcinoma of the skin, or in situ cervical cancer that has undergone potentially
             curative therapy

          -  Patient has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis

               -  Patients with previously treated brain metastases may participate provided they
                  are stable (without evidence of progression by imaging for at least 4 weeks prior
                  to the first dose of trial treatment and any neurologic symptoms have returned to
                  baseline), have no evidence of new or enlarging brain metastases, and are not
                  using steroids for at least 7 days prior to trial treatment

          -  Patient has a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to MK-3475

          -  Patient has an active autoimmune disease requiring systemic treatment within the past
             3 months or a documented history of clinically severe autoimmune disease, or a
             syndrome that requires systemic steroids or immunosuppressive agents; patients with
             vitiligo or resolved childhood asthma/atopy would be an exception to this rule;
             patients that require intermittent use of bronchodilators or local steroid injections
             would not be excluded from the study; the use of physiologic doses of corticosteroids
             may be approved after consultation with the protocol principal investigator (PI) and
             Cancer Immunotherapy Trials Network (CITN); patients with hypothyroidism stable on
             hormone replacement or Sjogren's syndrome will not be excluded from the study

          -  Patient has a history or current evidence of any condition, therapy, or laboratory
             abnormality that might confound the results of the trial, interfere with the patient's
             participation for the full duration of the trial, or is not in the best interest of
             the patient to participate, in the opinion of the treating investigator

          -  Patient has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Patient has uncontrolled intercurrent illness including, but not limited to, ongoing
             or active infection, interstitial lung disease, non-infectious pneumonitis,
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Patient is pregnant or breastfeeding, or expecting to conceive or father children
             within the projected duration of the trial, starting with the pre-screening or
             screening visit through 120 days after the last dose of trial treatment

               -  NOTE: pregnant women are excluded from this study; breastfeeding should be
                  discontinued if the mother is treated with MK-3475

               -  Men and nonpregnant, non-breast-feeding women may be enrolled if they are willing
                  to use 2 methods of birth control or are considered highly unlikely to conceive;
                  highly unlikely to conceive is defined as (1) surgically sterilized, or (2)
                  postmenopausal (a woman who is &gt;= 45 years of age and has not had menses for
                  greater than 1 year will be considered postmenopausal), or (3) not heterosexually
                  active for the duration of the study; the 2 birth control methods can be barrier
                  method or a barrier method plus a hormonal method to prevent pregnancy; subjects
                  should start using birth control from the screening visit throughout the study
                  period up to 120 days after the last dose of study therapy

               -  The following are considered adequate barrier methods of contraception:
                  diaphragm, condom (by the partner), copper intrauterine device, sponge, or
                  spermicide; appropriate hormonal contraceptives will include any registered and
                  marketed contraceptive agent that contains an estrogen and/or a progestational
                  agent (including oral, subcutaneous, intrauterine, or intramuscular agents)

               -  Patients should be informed that taking the study medication may involve unknown
                  risks to the fetus (unborn baby) if pregnancy were to occur during the study; in
                  order to participate in the study, they must adhere to the contraception
                  requirement (described above) for the duration of the study and during the
                  follow-up period described above; if there is any question that a subject will
                  not reliably comply with the requirements for contraception, that subject should
                  not be entered into the study

               -  Pregnancy: if a patient inadvertently becomes pregnant while on treatment with
                  MK-3475, the patient will immediately be removed from the study; the site will
                  contact the patient at least monthly and document the patient's status until the
                  pregnancy has been completed or terminated; the outcome of the pregnancy will be
                  reported without delay and within 24 hours if the outcome is a serious adverse
                  experience (e.g., death, abortion, congenital anomaly, or other disabling or
                  life-threatening complication to the mother or newborn); the study investigator
                  will make every effort to obtain permission to follow the outcome of the
                  pregnancy and report the condition of the fetus or newborn; if a male patient
                  impregnates his female partner the study personnel at the site must be informed
                  immediately and the pregnancy reported and followed

               -  Subjects who are breast-feeding are not eligible for enrollment

          -  Patient is human immunodeficiency virus (HIV) positive

        Note: patients who are human immunodeficiency virus (HIV) positive may participate IF they
        meet the following eligibility requirements:

          -  They must be stable on their anti-retroviral regimen, and they must be healthy from an
             HIV perspective

          -  They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL

          -  They must not be receiving prophylactic therapy for an opportunistic infection

               -  Patient has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg]
                  reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA]
                  [qualitative] is detected)

          -  Note: a positive hepatitis B serology indicative of previous immunization (i.e.,
             hepatitis B surface antibody [HBsAb]-positive and hepatitis B core antibody
             [HBcAb]-negative) or a fully resolved acute hepatitis B infection is not an exclusion
             criterion

               -  Has active non-infectious pneumonitis &gt;= grade 2; or history of grade 3
                  non-infectious pneumonitis within the past 12 months; or any history of grade 4
                  non-infectious pneumonitis

               -  History of other pulmonary disease such as emphysema or chronic obstructive
                  pulmonary disease (COPD), (forced expiratory volume in 1 second [FEV1] &lt; 60% of
                  predicted for height and age); pulmonary function tests (PFTs) are required in
                  patients with prolonged smoking history or symptoms of respiratory dysfunction

               -  Cardiovascular disease that meets one of the following: congestive heart failure
                  (New York Heart Association class III or IV), active angina pectoris, or recent
                  myocardial infarction (within the last 6 months)

               -  Prior organ allograft or allogeneic transplantation, if the transplanted tissue
                  is still in place

               -  Patient has had live vaccines within 30 days before the first dose of trial
                  treatment and while participating in the trial; examples of live vaccines
                  include, but are not limited to, the following: measles, mumps, rubella, chicken
                  pox, yellow fever, seasonal flu, H1N1 flu, rabies, bacille de Calmette et Gu√©rin
                  (BCG), and typhoid vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Nghiem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Immunotherapy Trials Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Institute Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Science Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

